Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Histamine H1 receptor

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1953

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Allergic rhinitis

3

Pruritus

3

Rhinitis

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Carson, L.E.|Campbell, C.C.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

EPA CompTox

3

FDA UNII

3

MERCK INDEX

3

PUBCHEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIHISTAMINES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIHISTAMINES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Aminoalkyl ethers

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DIPHENYLPYRALINE

33361OE3AV

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1953

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic rhinitis

Diphenylpyraline is an antihistamine that prevents but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline ma...

y exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa. Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.

DIPHENYLPYRALINE HYDROBROMIDE

1QG9Y7X51O

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1953

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic rhinitis

Diphenylpyraline is an antihistamine that prevents but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline ma...

y exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa. Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.

DIPHENYLPYRALINE HYDROCHLORIDE

G9FU7F1E87

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1953

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic rhinitis

Diphenylpyraline is an antihistamine that prevents but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline ma...

y exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa. Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1